GPP
ESPR icon

Great Point Partners’s Esperion Therapeutics ESPR Stock Holding History

Great Point Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,791,594
Closed -$12.9M – 32
2024
Q2 		$12.9M Sell
5,791,594
-2,208,406
-28% -$5.2M 2.46% 18
2024
Q1 		$21.4M Buy
+8,000,000
New +$19.4M 3.34% 11
2015
Q3 		– Sell
-8,400
Closed -$687K – 39
2015
Q2 		$687K Buy
+8,400
New +$822K 0.27% 31

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Great Point Partners's ESPR Position: Q3 2024 in Review

Great Point Partners sold out of Esperion Therapeutics (ESPR) in Q3 2024, closing a stake of 5,791,594 shares — an estimated $12.9M sold.

Great Point Partners first reported a position in ESPR in Q2 2015 and held it in 3 quarters. The position peaked at $21.4M in Q1 2024. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Great Point Partners reported no remaining Esperion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Great Point Partners sold 5,791,594 Esperion Therapeutics shares in Q3 2024, an estimated $12.9M.
  • Great Point Partners first reported a position in Esperion Therapeutics in Q2 2015 and held it in 3 quarters.
  • Great Point Partners's Esperion Therapeutics position peaked at $21.4M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.